[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100392023":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":28,"centralContacts":38,"locations":45,"responsibleParty":62,"collaborators":43,"id":65,"slug":43,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":43,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":43,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":84,"overallStatus":89,"whyStopped":43,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Ruijin Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"SOX Chemotherapy","EXPERIMENTAL","Three preoperative and three postoperative cycles of SOX chemotherapy\n\nA cycle consist of Day 1: Oxaliplatin 130mg\u002FM2 intravenous Day 1-14 Tegafur gimeracil oteracil potassium capsule 80mg\u002FM2 oral (twice daily)\n\nRepeated every 21st day",[13],"Drug: Chemotherapy",{"label":15,"type":16,"description":17,"interventionNames":18},"FLOT Chemotherapy","ACTIVE_COMPARATOR","Four preoperative and four postoperative cycles of FLOT chemotherapy\n\nA cycle consist of Day 1 5-fluorouracil(5-FU) 2600mg\u002FM2 administered via intravenous peripherally inserted central venous catheter(PICC) for 24 hour Leucovorin 200mg\u002FM2 intravenous Oxaliplatin 85mg\u002F M2 intravenous Docetaxel 50mg\u002FM2 intravenous\n\nRepeated every 15th day",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Chemotherapy","Perioperative chemotherapy will be administered according to description in two arms.",[15,9],[26,27],"FLOT chemotherapy","SOX chemotherapy",[29,32,35],{"name":30,"affiliation":5,"role":31},"Birendra K Sah, PH D","PRINCIPAL_INVESTIGATOR",{"name":33,"affiliation":5,"role":34},"Chen Li, PH D","STUDY_DIRECTOR",{"name":36,"affiliation":5,"role":37},"Zhenggang Zhu, PH D","STUDY_CHAIR",[39],{"name":40,"role":41,"phone":42,"phoneExt":43,"email":44},"Birendra K Sah, Ph D","CONTACT","0086-13817516354",null,"rjsurgeon@hotmail.com",[46],{"facility":47,"status":43,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Ruijin Hospital Shanghai Jiaotong University School of Medicine","Shanghai","Shanghai Municipality","200025","China","CN",{"type":54,"coordinates":55},"Point",[56,57],121.45806,31.22222,{"lat":57,"lon":56},[60],{"name":40,"role":41,"phone":61,"phoneExt":43,"email":44},"008613817516354",{"type":31,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":43,"oldOrganization":43},"BIRENDRA KUMAR SAH","Surgeon","100392023",false,"NCT04384601","Dragon III-Phase 3: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer","Efficacy Study of FLOT Versus SOX Regimen as Neoadjuvant Chemotherapy for Patients With Locally Advanced Gastric Cancer: A Phase 3 Multi-center Randomized Controlled Trial","Inclusion Criteria:\n\n* Histology confirmed non-obstructive adenocarcinoma of stomach or esophago-gastric junction.\n* Clinical stage: Clinical Tumor-Node-Metastasis (cTNM:) stage III\n* Performance status: Eastern Cooperative Oncology Group (ECOG) ≤ 2 (normal to symptomatic but in bed less than half the day)\n* Clinically fit for systemic chemotherapy and gastric cancer surgery, i.e. adequate renal, hepatic, hematologic and pulmonary function.\n* Written informed consent\n\nExclusion Criteria:\n\n* Clinically unfit for systemic chemotherapy and gastric cancer surgery, i.e. uncontrolled cardiac disease, or other clinically significant uncontrolled comorbidities, unable to undergo general anesthesia\n* Distant metastases (including retroperitoneal lymph node)\n* Locally advanced inoperable disease (Clinical assessment)\n* Relapse of gastric cancer\n* Malignant secondary disease\n* Prior chemo or radio therapy\n* Inclusion in another clinical trial\n* Known contraindications or hypersensitivity for planned chemotherapy","ALL","18 Years","80 Years",{"count":75,"type":76},246,"ESTIMATED","INTERVENTIONAL",[79],"PHASE3","DRAGON III research, Neoadjuvant Chemotherapy (FLOT versus SOX) for Gastric Cancer, is an investigator initiated; phase 3, open label, multi-center randomized controlled study.",[82,83],"Gastric Cancer","Neoadjuvant Chemotherapy",[82,85,86,87,88],"Gastric Adenocarcinoma","Stomach Cancer, Adenocarcinoma","Chemotherapy Effect","Neoadjuvant chemotherapy","NOT_YET_RECRUITING","2021-07-15",{"date":92,"type":93},"2021-07-19","ACTUAL",{"date":95,"type":76},"2021-09",{"date":97,"type":76},"2027-09",{"name":5,"class":6},1]